Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate

PURPOSE: Reducing the dosing frequency of antipsychotics (APs) with long-acting injectables (LAIs) such as once-monthly paliperidone palmitate (PP1M) can improve adherence and clinical outcomes for schizophrenia patients. This US study compared physical and psychiatric comorbidity-related outcomes,...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Charmi, Emond, Bruno, Lafeuille, Marie-Hélène, Côté-Sergent, Aurélie, Lefebvre, Patrick, Tandon, Neeta, El Khoury, Antoine C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061019/
https://www.ncbi.nlm.nih.gov/pubmed/31786737
http://dx.doi.org/10.1007/s40801-019-00172-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061019/
https://www.ncbi.nlm.nih.gov/pubmed/31786737
http://dx.doi.org/10.1007/s40801-019-00172-9

Ejemplares similares